Complete disappearance of liver metastases in a patient with iodine-refractory differentiated thyroid cancer subjected to sorafenib re-challenge

Endocrine. 2015 Dec;50(3):824-5. doi: 10.1007/s12020-015-0570-5. Epub 2015 Mar 10.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Female
  • Humans
  • Iodine Radioisotopes / therapeutic use
  • Liver / pathology
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / secondary
  • Middle Aged
  • Niacinamide / analogs & derivatives*
  • Niacinamide / pharmacology
  • Niacinamide / therapeutic use
  • Phenylurea Compounds / pharmacology
  • Phenylurea Compounds / therapeutic use*
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Sorafenib
  • Thyroid Neoplasms / drug therapy*
  • Thyroid Neoplasms / pathology

Substances

  • Antineoplastic Agents
  • Iodine Radioisotopes
  • Phenylurea Compounds
  • Niacinamide
  • Sorafenib
  • Protein-Tyrosine Kinases